Related references
Note: Only part of the references are listed.Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy
I. M. E. Desar et al.
CANCER TREATMENT REVIEWS (2009)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
I. Tamaskar et al.
ANNALS OF ONCOLOGY (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
John D. Gordan et al.
CANCER CELL (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Thomas E. Hutson et al.
ONCOLOGIST (2008)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Association between development of hypothyroidism and improved survival in patients with head and neck cancer
Marc Nelson et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells
Faith B. Davis et al.
CANCER RESEARCH (2006)
Is there a need to redefine the upper normal limit of TSH?
G. Brabant et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis
JJ Bergh et al.
ENDOCRINOLOGY (2005)
Subclinical thyroid disease - Scientific review and guidelines for diagnosis and management
MI Surks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy
JA Fagin
JOURNAL OF ENDOCRINOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials
BC Leibovich et al.
CANCER (2003)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)